Get started
Work

Dual CDKN2A/MTAP loss compared to CDKN2A loss alone and response to immune-checkpoint inhibitors (ICI) in advanced solid tumors.

Year: 2022
Type: conference-abstract
DOI: 10.1200/jco.2022.40.16_suppl.2622
Authors: Elio Adib, Amin Nassar, Talal El Zarif, Neil Kale, Mehrdad Rakaee, Tarek H. Mouhieddine, Sarah Abou Alaiwi, Dory Freeman, Muhieddine Labban, Eli Akl, Robert I. Haddad, F. Stephen Hodi, Guru P. Sonpavde, Marios Giannakis, David A. Braun, Alexander Gusev, Toni K. Choueiri, Erin Overstreet, Everett Stone, David J. Kwiatkowski
Institutions: Brigham and Women's Hospital, Dana-Farber Cancer Institute, Dana-Farber Brigham Cancer Center, Worcester Polytechnic Institute, UiT The Arctic University of Norway, Harvard University, Dana-Farber/Harvard Cancer Center, Johns Hopkins Medicine, The University of Texas at Austin
Language: English
Subfield: Oncology
Field: Medicine
Open Access status: closed
OpenAlex ID: W4286294433
Cites:
Cited by: 5
Related to: 10